FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Tumor Biomarker Changes Following Pre-Surgical Treatment with 500 mg Fulvestrant Plus Anastrozole Versus 500 mg Fulvestrant Alone and 1 mg Anastrozole Alone.:

(2010) J. Robertson et al.   CANCER RESEARCH

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Third consensus on medical treatment of metastatic breast cancer

(2009) S. Beslija et al.   ANNALS OF ONCOLOGY

Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft Model

(2008) L. F. Macedo et al.   CANCER RESEARCH

Pharmacokinetic Profile of the Fulvestrant Loading Dose Regimen in Postmenopausal Women with Hormone Receptor–Positive Advanced Breast Cancer

(2008) Peter McCormack et al.   Clinical Breast Cancer

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer

(2008) M. Dowsett et al.   CLINICAL CANCER RESEARCH